These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1966 related items for PubMed ID: 20087739

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M.
    J Clin Oncol; 2009 Nov 20; 27(33):5538-46. PubMed ID: 19786658
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
    Kim HJ, Cui X, Hilsenbeck SG, Lee AV.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
    [Abstract] [Full Text] [Related]

  • 6. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
    Prat A, Baselga J.
    Nat Clin Pract Oncol; 2008 Sep 01; 5(9):531-42. PubMed ID: 18607391
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.
    Clin Cancer Res; 2007 Apr 15; 13(8):2329-34. PubMed ID: 17438091
    [Abstract] [Full Text] [Related]

  • 9. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M, Bendahl PO.
    Breast Cancer Res Treat; 2008 May 15; 109(2):351-7. PubMed ID: 17636399
    [Abstract] [Full Text] [Related]

  • 10. Enhancing the efficacy of hormonal agents with selected targeted agents.
    Johnston SR.
    Clin Breast Cancer; 2009 Jun 15; 9 Suppl 1():S28-36. PubMed ID: 19561004
    [Abstract] [Full Text] [Related]

  • 11. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ, Kolesar JM.
    Clin Ther; 2009 Jun 15; 31 Pt 2():2332-48. PubMed ID: 20110044
    [Abstract] [Full Text] [Related]

  • 12. Is triple negative a prognostic factor in breast cancer?
    Nishimura R, Arima N.
    Breast Cancer; 2008 Jun 15; 15(4):303-8. PubMed ID: 18369692
    [Abstract] [Full Text] [Related]

  • 13. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G.
    Breast Cancer Res Treat; 2010 Aug 15; 122(3):685-97. PubMed ID: 19859802
    [Abstract] [Full Text] [Related]

  • 14. Simultaneous targeting of estrogen receptor and HER2 in breast cancer.
    Azim HA, Piccart MJ.
    Expert Rev Anticancer Ther; 2010 Aug 15; 10(8):1255-63. PubMed ID: 20735311
    [Abstract] [Full Text] [Related]

  • 15. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
    Glück S, Arteaga CL, Osborne CK.
    Clin Cancer Res; 2011 Sep 01; 17(17):5559-61. PubMed ID: 21764887
    [Abstract] [Full Text] [Related]

  • 16. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
    Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ.
    Nat Clin Pract Oncol; 2006 May 01; 3(5):269-80. PubMed ID: 16683005
    [Abstract] [Full Text] [Related]

  • 17. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M, Bauer K, Pare M.
    Breast Cancer Res Treat; 2010 Feb 01; 120(1):217-27. PubMed ID: 19629680
    [Abstract] [Full Text] [Related]

  • 18. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R, O'Regan RM.
    Clin Breast Cancer; 2010 Nov 01; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [Abstract] [Full Text] [Related]

  • 19. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W, Esteva FJ.
    Eur J Cancer; 2008 Dec 01; 44(18):2806-12. PubMed ID: 19022660
    [Abstract] [Full Text] [Related]

  • 20. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.
    van de Ven S, Smit VT, Dekker TJ, Nortier JW, Kroep JR.
    Cancer Treat Rev; 2011 Oct 01; 37(6):422-30. PubMed ID: 21177040
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 99.